Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning  Jennifer Vaughn, MD, MSPH, Mohamed L. Sorror, MD, MSc, Thomas Chauncey, MD, PhD, Michael A. Pulsipher, MD, Richard T. Maziarz, MD, Michael B. Maris, MD, Parameswaran N. Hari, MD, MRCP, MS, Ginna G. Laport, MD, Georg-Nikolaus Franke, Edward Agura, MD, Amelia Langston, MD, Andrew Rezvani, Rainer F. Storb, MD, Brenda M. Sandmaier, MD, David G. Maloney, MD, PhD  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, Pages S88-S89 (February 2015) DOI: 10.1016/j.bbmt.2014.11.107 Copyright © 2015 Terms and Conditions

Figure 1 Cumulative incidences of (A) NRM and relapse (B) OS and DFS. Biology of Blood and Marrow Transplantation 2015 21, S88-S89DOI: (10.1016/j.bbmt.2014.11.107) Copyright © 2015 Terms and Conditions